Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high brain tissue delivery Lexaria Bioscience's (NASDAQ: LEXX) just-concluded oral tetrahydrocannabinol (“THC”) absorption animal study, THC-A21-1, yielded promising results on the effectiveness of the company’s patented DehydraTECH(TM) drug delivery technology. The study, performed by a leading, independent laboratory, involved 20 male Sprague Dawley rats split into…